What Does Qiagen (QGEN) Do? – Stock Outlook, Earnings, Market Cap, Related Stocks, and Headquarters Overview
Qiagen (QGEN) is a global life sciences and diagnostics company that supplies molecular diagnostics and sample preparation/analysis technologies. Its earnings and stock price move in line with recurring demand for sample preparation consumables and molecular diagnostics/R&D demand, making it a diagnostics and life sciences name with strength in specialty diagnostics such as latent tuberculosis testing.
🏢 What kind of company is Qiagen?
Qiagen (QGEN) is a global life sciences and diagnostics company headquartered in the Netherlands and Germany, with molecular diagnostics and sample preparation/analysis technologies at its core. It provides integrated solutions for extracting, purifying, and analyzing genetic and molecular information from samples, and has supplied products to the diagnostics, research, and pharmaceutical markets.
The business consists of sample preparation and purification kits, molecular diagnostics and analysis instruments and consumables, and molecular diagnostic tests for tuberculosis, infectious diseases, and more. It offers an integrated solution connecting samples to insights (sample to insight), and along with instrument sales, the recurring demand for kits and consumables provides a stable revenue base.
💰 How does Qiagen make money?
| Business Segment | Revenue Share | Description | ||||||
|---|---|---|---|---|---|---|---|---|
| Sample Preparation & Consumables | Core Business | Sample preparation/purification kits and consumables | ||||||
| Molecular Diagnostic Tests | Growth Driver | Molecular diagnostic tests for tuberculosis, infectious diseases, and more | ||||||
| Analysis Instruments & Software | Foundation Business | Molecular analysis instruments and software |
| 종목 | 회사명 | 가격 | 등락 | 시총 | PER | PBR | ROE | 배당률 |
|---|---|---|---|---|---|---|---|---|
 TECH | Bio-Techne Corp | $72.03 | +0.0% | $11.3B | 103.5 | 5.4 | 5.34% | 0.44% |
 BIO | Bio-Rad Laboratories Inc | $326.72 | -0.2% | $8.8B | 53.8 | 1.3 | 2.5% | - |
| 종목 | 회사명 | 가격 | 등락 | 시총 | PER | PBR | ROE | 배당률 |
|---|---|---|---|---|---|---|---|---|
| TMO | Thermo Fisher Scientific Inc | $576.77 | +0.1% | $214.3B | 31.0 | 4.1 | 13.53% | 0.32% |
| ILMN | Illumina Inc | $205.09 | +5.3% | $31.0B | 37.2 | 11.7 | 33.82% | - |
✅ Qiagen investor checkpoints
Key checkpoints for Qiagen investors. As a diagnostics and life sciences name, molecular diagnostics demand, recurring consumables demand, pharmaceutical and R&D budgets, and the competitive environment serve as the core short- to medium-term variables.
| Checkpoint | What to Verify | Current Status |
|---|---|---|
| 🧬 Diagnostics Demand | Molecular diagnostics and infectious disease testing demand | Worth Monitoring |
| 🔁 Consumables Demand | Recurring demand for sample preparation kits and consumables | Stable Foundation |
| 🦠 Specialty Diagnostics | Growth of specialty tests such as latent tuberculosis | Monitor for Growth |
| 🏦 R&D Budgets | Pharmaceutical and biotech R&D budgets | Worth Monitoring |
Changes in diagnostics demand, including infectious disease testing, can impact revenue. Shifts in pharmaceutical and R&D budgets and biotech funding conditions can affect demand, and intensifying molecular diagnostics and tools competition along with currency fluctuations can also weigh on profitability.
Qiagen is a global life sciences and diagnostics company providing integrated solutions from sample preparation to molecular diagnostics. Molecular diagnostics demand, recurring consumables demand, and growth in specialty diagnostics are core variables to monitor, and a phased buying approach with a long-term perspective is recommended, weighing the stability of recurring demand against demand and competitive risks.
이 글은 2026년 6월 5일 기준 정보입니다.